All subjects in this study have previously been in an Idenix HCV study and received study drug for 3 consecutive days. Subjects who had received placebo in a previous Idenix study will not be enrolled in this study. In this study, researchers will try to find answers to these questions: * How much (if any) hepatitis C virus is in your blood after stopping your Idenix study drug? * Is your hepatitis C virus possibly resistant to treatment with the Idenix study drug or similar drugs?
The data obtained from this study will be used to further understand the long-term efficacy of Idenix DAAs used to treat HCV infection and to further understand HCV resistance to Idenix DAAs.
Study Type
OBSERVATIONAL
Enrollment
145
Durability of Sustained viral response [SVR]
To evaluate the durability of sustained virological response (SVR). Plasma HCV RNA levels will be monitored over time.
Time frame: every 3 months
Kinetics of resistant variants
To describe the kinetics of resistant variants to Idenix direct acting antivirals (DAAs) by HCV RNA sequencing. The presence of each identified resistant variant in the viral population will be descriptively evaluated until the viral population consists entirely of wild-type virus or over a period of 3 years, whichever comes first.
Time frame: every 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.